Opinion on Biotechnology in Middle East and Africa

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
Expert View
Expert View

The impact of IT on next-generation DNA sequencing

The mystery behind why some have a genetic disposition to a certain disease, or why a medicine works for some and not for others, might be revealed sooner than many had anticipated. In the past couple of months, several significant breakthroughs in DNA sequencing technology have been made, giving hope to the researchers that the coveted $1,000 genome is just around the corner.

Published By Datamonitor
21 Apr 2008
Expert View
Expert View

Roche looks to maximize Genentech potential

Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990. While Genentech has historically operated independently from its parent company, it remains to be seen whether the merger will damage an operating structure which has allowed the biotech firm to drive Roche's growth performance in recent years.

Published By Datamonitor
23 Jul 2008
CommentWire
CommentWire

RNAi: is the industry losing faith?

RNAi-based drugs were widely viewed as the next big thing after monoclonal antibodies; however, the initial wave of interest seems to be slowing down, largely due to financial constraints. Novartis and Roche recently ended their respective research in this field, highlighting the pharmaceutical industry's immediate need to boost its top line.

Published By Datamonitor
25 Nov 2010
CommentWire
CommentWire

Oxford GlycoSciences/Teva: identifying Israeli opportunities

The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.

Published By Datamonitor
21 Nov 2001
Expert View
Expert View

Opportunity knocks for big pharmaceutical companies in the credit crunch

Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich. As a result, pharmaceutical companies should weather the financial storm and be able to make significant acquisitions, unlike their biotechnology counterparts.

Published By Datamonitor
09 Oct 2008
CommentWire
CommentWire

Nabi: pharmaceutical giants should cough up for smoking vaccine

Positive interim results, assessing the antibody response and safety of a 400mcg, six-dose immunization schedule of Nabi Biopharmaceuticals' NicVAX, provide a new indication of the vaccine's potential to treat nicotine addiction and prevent smoking relapse. These results make the product a more attractive licensing proposition as Nabi gears up to initiate pivotal Phase III trials.

Published By Datamonitor
25 Jul 2008
ResearchWire
ResearchWire

Monoclonal antibodies: attractive market dominated by leading drugs

Published By Datamonitor
12 Jul 2007
ResearchWire
ResearchWire

mAbs: new asthma therapies to drive the market

Published By Datamonitor
23 Jun 2006

« | 1 | 2 | » »|

No help is available.